2025年7月11日，创新药企ETF(560900)盘中涨超2%，截至13:14，该基金盘中换手11.19%，市场交投活 跃。跟踪指数中证创新药产业指数(931152)强势上涨1.85%，成分股凯莱英(002821)上涨10.00%，药明康 德(603259)上涨9.99%，博瑞医药(688166)上涨8.56%，特宝生物(688278)，康龙化成(300759)等个股跟 涨。 消息面上，7月10日晚间，药明康德发布2025年半年度业绩预告，预计上半年实现营收约207.99亿元， 同比增长约20.64%；预计实现归属于股东净利润约85.61亿元，同比增长约101.92%。经调整归母净利润 约63.15亿元，同比增长约44.43%；扣非后净利润约55.82亿元，同比增长约26.47%。 截至2025年7月10日，创新药企ETF(560900)近1周累计涨幅居可比基金第一。创新药企ETF(560900)近3 月规模增长470.91万元，近半年份额增长800.00万份，均实现显著增长。 主动管理方面，摩根新兴动力基金（A类：377240 C类：014642）从长期视角争取把握新兴产业趋势； 摩根智慧互联基金（A类： ...

2025年5月23日，创新药企ETF(560900)盘中走强，一度涨超1.5%，截至09:53，该基金跟踪指数中证创 新药产业指数(931152)强势上涨1.17%，成分股众生药业(002317)上涨10.02%，科伦药业(002422)上涨 6.09%，贝达药业(300558)上涨5.29%，信立泰(002294)，泰格医药(300347)等个股跟涨。截至5月22日， 创新药企ETF(560900)近1周累计上涨4.06%。 伴随AI驱动新一轮科技浪潮的兴起，摩根资产管理整合旗下"全球视野投科技"产品线，从主动管理到被 动投资产品，助力投资者从全球视野布局优质科技企业，把握时代浪潮下的投资机遇。 主动管理方面，摩根新兴动力基金（A类：377240 C类：014642）从长期视角争取把握新兴产业趋势； 摩根智慧互联基金（A类：001313 C类：016919）聚焦人工智能相关领域机会；摩根动力精选基金（A 类：006250 C类：013137）关注新能源车产业链、人形机器人等领域；摩根慧选成长基金（A类： 008314 C类：008315），布局A+H优质成长企业；摩根太平洋科技基金（PRC人民币对冲（累计） ...

Group 1 - The Innovation Drug ETF (560900) increased by 1.60% with a turnover of 4.89% and a transaction volume of 1.6387 million yuan as of May 21, 2025 [1] - The CSI Innovation Drug Industry Index (931152) rose by 1.24%, with constituent stocks such as Sangfor Technologies (688336) up by 19.99%, Kanghong Pharmaceutical (002773) up by 6.38%, and Sinocelltech (688520) up by 6.23% [1] - As of May 20, the Innovation Drug ETF (560900) saw a year-to-date increase of 1 million shares, ranking among the top in terms of new share growth compared to similar funds [1] Group 2 - On May 20, Sangfor Technologies announced a licensing agreement with related parties Sangfor Pharmaceutical and Shenyang Sangfor, involving exclusive global development, production, and commercialization rights for a product with Pfizer, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1] - The pharmaceutical and biotechnology industry is characterized by a resonance of innovation and domestic demand, with innovation being the core direction of the pharmaceutical sector according to Industrial Securities [1] Group 3 - The Innovation Drug ETF closely tracks the CSI Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2] - Morgan Asset Management integrates its "Global Vision Investment Technology" product line to help investors layout quality technology companies globally, seizing investment opportunities amid the new wave of technology driven by AI [2] Group 4 - In passive investment, Morgan Hang Seng Technology ETF (QDII) provides a one-click layout for Hong Kong stock technology assets, while Morgan CSI Innovation Drug Industry ETF (560900) offers a one-click layout for Chinese innovative pharmaceutical companies [3] - Morgan NASDAQ 100 Index Fund (QDII) allows for a one-click investment in global technology leaders [3]